⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

October 10, 2016Expert Review of Clinical PharmacologyOpen Access

Early drug development: assessment of proarrhythmic risk and cardiovascular safety

View Full Paper

Ask AI

Bookmark

Share

Design

Review

Authors

RLRobert M. LesterCelerion (United States)JOJoy OlbertzBrigham and Women's Hospital

Discussion

Loading...

Member takes

Implication

Supports shift to mechanistic CiPA paradigms in early development; leaves open optimal integration with clinical ECG data.

Key Points

Key points are not available for this paper at this time.

Cite This Study

Lester et al. (2016) studied this question.

synapsesocial.com/papers/6a70b0ff31a3df824328f29a https://doi.org/10.1080/17512433.2016.1245142

View Full Paper

Ask AI

Bookmark

Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1An introduction to QT interval prolongation and non‐clinical approaches to assessing and reducing risk2010 · 161 citations
2Dealing with hERG liabilities early: diverse approaches to an important goal in drug development2010 · 24 citations
3Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea‐pig model2008 · 75 citations
4Drug-induced QT prolongation and proarrhythmia: an inevitable link?2007 · 39 citations
5Screening for Acute<i>I</i><sub>Kr</sub>Block Is Insufficient to Detect Torsades de Pointes Liability2014 · 163 citations